Marco Meglio

Panelists review emerging real-world and ECTRIMS data demonstrating that the updated McDonald criteria improve earlier MS diagnosis while maintaining diagnostic accuracy across diverse clinical settings.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is GLP-1s & migraine!

Experts discuss how the updated McDonald criteria redefine radiologically isolated syndrome and explore the clinical, imaging, and access challenges of diagnosing and treating MS before symptom onset.

A panel of MS experts breaks down the most impactful updates to the 2024 McDonald criteria, highlighting how new biomarkers, imaging features, and diagnostic flexibility are reshaping earlier and more accurate MS diagnosis.

For Purple Day, M. Scott Perry, MD, a leader within the epilepsy community, shared thoughts and perspectives on the persistent gaps in epilepsy awareness, the hope for precision therapies, and the need for holistic care.

Apply for a $40,000 international MS research award honoring senior women scientists advancing care for women; submissions close June 12, 2026.

The FDA granted accelerated approval to tividenofusp alfa for Hunter syndrome, introducing the first enzyme replacement therapy designed to cross the blood-brain barrier and target neurologic disease.

The chief medical officer at Edgewise discussed long-term MESA data showing sustained functional stabilization with sevasemten in Becker muscular dystrophy and its potential as a disease-modifying therapy.

The division chief of neuroimmunology at Brigham and Women’s Hospital provided clinical insights on a recently published study in JAMA Neurology covering EBNA-1 antibodies as a diagnostic clue in neuroinflammatory diseases like multiple sclerosis. [WATCH TIME: 4 minutes]

In a plain language summary of the ADHERE trial, subcutaneous efgartigimod improved disability and reduced relapse risk by 61% in CIDP, with sustained benefit and a favorable safety profile.

The assistant professor of medicine at the University of Toronto discussed population-level evidence suggesting MS may precede EBV infection in rare cases and its implications for disease pathogenesis and diagnosis.

A large JAMA Neurology study found that persistently elevated EBNA-1 antibody titers across serial samples strongly differentiated multiple sclerosis from MOGAD and NMOSD, supporting its role as an adjunct diagnostic biomarker.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is chronic traumatic encephalopathy!

In honor of Down Syndrome Awareness Day, neurologist Elizabeth Head, PhD, discusses neurologic comorbidities, biomarker advances, and emerging precision medicine approaches in Down syndrome–associated Alzheimer disease.

Early ASPIRO trial data show autologous stem-cell dopamine precursors stay safe at 12 months, with improved PD motor scores and PET-confirmed grafting.

Two phase 3 ADAGIO trials test Cobenfy for Alzheimer’s agitation, assessing muscarinic modulation safety and efficacy as a potential new dementia care option.

UK platform trial enrolls 1,600 with Parkinson’s to rapidly test telmisartan, terazosin and new candidates via shared placebo and virtual visits.

The division chief of neuroimmunology at Brigham and Women’s Hospital discusses longitudinal EBNA-1 antibody data and its potential role as a complementary biomarker to distinguish MS from related neuroinflammatory diseases.

A global survey of neurologists and psychiatrists found that although tetrabenazine remains widely used for tardive dyskinesia and Huntington disease–related chorea, side effects frequently prevent optimal dose titration and lead to treatment discontinuation.

A post hoc analysis of the AMPA observational study found that adjunctive perampanel did not worsen daytime sleepiness over 12 months in patients with focal epilepsy while maintaining substantial seizure reduction.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is cerebroprotection in stroke!

A randomized trial in patients with CIDP found that adding intravenous methylprednisolone to IVIg did not significantly increase remission rates and was associated with thromboembolic safety concerns.

Phase 3 data show azetukalner cuts monthly focal seizures in refractory epilepsy, offering a novel KV7 option ahead of 2026 FDA filing.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with AAN President Natalia Rost, MD, MPH. [LISTEN TIME: 16 minutes]

A comparative analysis presented at the 2026 MDA Conference suggests the intrathecal gene therapy Itvisma may achieve similar motor outcomes to nusinersen and risdiplam in patients with spinal muscular atrophy.

John Crowley, chief executive officer of the Biotechnology Innovation Organization, discusses the evolving biotechnology ecosystem, emerging therapeutic technologies, and ongoing policy challenges shaping the future of rare disease innovation.

SAFARI44 launches a phase 3 test of del-zota for DMD exon 44 skipping, tracking muscle function and dystrophin gains over 54 weeks.

Phase 2 CANYON data show sevasemten keeps LVEF steady and NT-proBNP stable in adults with Becker muscular dystrophy, hinting at heart protection.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Seronegative generalized myasthenia gravis!

PrimeC shows significant survival gains and slowed progression in ALS phase 2b follow-up, fueling plans for larger late-stage trials.